WHO ICTRP trial
Phase I trial of eribulin/S-1 combination therapy for advanced/recurrent breast…
JPRN-UMIN000009716 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-UMIN000009716 |
|---|---|
| Public title | Phase I trial of eribulin/S-1 combination therapy for advanced/recurrent breast cancer pretreated by anthracycline and taxane |
| Scientific title | Phase I trial of eribulin/S-1 combination therapy for advanced/recurrent breast cancer pretreated by anthracycline and taxane - Phase I trial of eribulin/S-1 combination therapy for advanced/recurrent breast cancer pretreated by anthracycline and taxane |
| Primary sponsor | Depertment of medical oncology, Kinki University Hospital, Faculty of medicine |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase I |
| Countries | Japan |
| Conditions | Advanced and recurrent breast cancer |
| Interventions | Combination therapy of Eribulin and S1 |
| Registration date | Jul 1, 2013 |
| Target size | 12 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: